Therapeutic approaches targeting MYC-Driven prostate cancer

RJ Rebello; RB Pearson; RD Hannan; L Furic

Journal article

Therapeutic approaches targeting MYC-Driven prostate cancer

RJ Rebello, RB Pearson, RD Hannan, L Furic

Genes | MDPI | Published : 2017

DOI: 10.3390/genes8020071

Download PDF

Abstract

The transcript encoding the proto-oncogene MYC is commonly overexpressed in prostate cancer (PC). MYC protein abundance is also increased in the majority of cases of advanced and metastatic castrate-resistant PC (mCRPC). Accordingly, the MYC-directed transcriptional program directly contributes to PC by upregulating the expression of a number of pro-tumorigenic factors involved in cell growth and proliferation. A key cellular process downstream of MYC activity is the regulation of ribosome biogenesis which sustains tumor growth. MYC activity also cooperates with the dysregulation of the phosphoinositol-3-kinase (PI3K)/AKT/mTOR pathway to promote PC cell survival. Recent advances in the under..

View full abstract

University of Melbourne Researchers

Richard Rebello Author

Richard Pearson Author

Related Projects (2)

ONCOGENIC SIGNALING AND CANCER THERAPY

Central to improving the management of patients with cancer is an understanding of the molecular drivers of cancer. Based on our fundamental..

Regulation of cell growth, proliferation and senescence by AKT

Ribosome synthesis and function are critical for normal cell growth and division and hence this process is exquisitely regulated. Conversely..

Grants

Awarded by National Science Foundation

Funding Acknowledgements

This work was supported by Cancer Australia (CA 1084546 to Ross D. Hannan, Richard B. Pearson, and Luc Furic); Prostate Cancer Foundation of Australia (YI 0310 to Luc Furic and CG 1511 to Richard B. Pearson, Ross D. Hannan, and Luc Furic); National Health and Medical Research Council (Program Grant 1053792 and Project Grant 1004881 to R. B. Pearson and Ross D. Hannan; Senior Research Fellowships to Richard B. Pearson and Ross D. Hannan) and the Department of Health and Human Services acting through the Victorian Cancer Agency (MCRF16007 to Luc Furic).